KZIA - ノボゲン (Kazia Therapeutics Limited) ノボゲン

 KZIAのチャート


 KZIAの企業情報

symbol KZIA
会社名 Kazia Therapeutics Ltd (ノボゲン)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Miscellaneous  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カジア・セラピュティクス(Kazia Therapeutics Limited)(旧名:Novogen Limited)はがん治療の開発に従事するオンコロジーバイオテクノロジー会社である。同社は主に医薬品の研究・開発を行う。同社はスーパーベンゾピラン(SBP)技術および抗トロポミオシン(ATM)2つの医薬プラットフォームを有する。そのプラットフォームは多様な腫瘍学的適応症にわたり各種の薬物候補を産生する。同社の製品候補には、Cantrixil(TRX-E-002-1)、Anisina(ATM-3507)、Trilexium(TRX-E-009-1)がある。Cantrixilの適応症は卵巣がんであり、Trilexiumの適応症はびまん性真性中枢神経膠腫(DIPG)である。Anisinaの最初の標的小児適応症は神経芽腫である。CantrixilはSBP技術から生まれたリード開発候補者である。Anisinaは、癌細胞のアクチン細胞骨格を標的とする化学療法へのアプローチである。Trilexium(TRX-E-009-1)は、SBPの第2候補薬候補である。   ノボゲンはオ―ストラリアの製薬会社。主に、がんや更年期障害などの治療薬の開発に従事。原子や化学構成成分を使用してベンゾピラン分子骨格に基づく化合物を構築する。ス―パ―ベンゾピランの搾取の早期段階にある。製薬候補の「Trilexium」は、卵巣がんと多形性膠芽腫を対象にした治療薬である。   Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
本社所在地 Level 5 20 George St Hornsby New South Wales 2077 AUS
代表者氏名 James B. Garner ジェームズ・B・ガーナー
代表者役職名 Chief Executive Officer Executive Director
電話番号 +61 2-9878-0088
設立年月日
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 16人
url www.novogen.com
nasdaq_url https://www.nasdaq.com/symbol/kzia
adr_tso 1742974
EBITDA EBITDA(百万ドル) -7.60277
終値(lastsale) 3.1056
時価総額(marketcap) 5412980.0544
時価総額 時価総額(百万ドル) 13.23090
売上高 売上高(百万ドル) 0.08485
企業価値(EV) 企業価値(EV)(百万ドル) 8.99009
当期純利益 当期純利益(百万ドル) -4.29995
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Kazia Therapeutics Ltd (ADR) revenues decreased 52% to A$119K. Net loss decreased 43% to A$6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative expense decrease of 28% to A$5.6M (expense) Research and development expense decrease of 12% to A$9.8M (expense).

 KZIAのテクニカル分析


 KZIAのニュース

   Biotech Kazia taps Bells for entitlement offer  2020/09/30 00:51:43 The Australian Financial Review
Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.
   Kazia inks clinical pact with Dana-farber Cancer Institute for its lead asset in primary CNS lymphoma (NASDAQ:KZIA)  2020/09/22 15:35:17 Seeking Alpha
Kazia Therapeutics (KZIA +0.9%) has collaborated with Dana-Farber Cancer Institute (DFCI), to investigate its lead drug, paxalisib (formerly GDC-0084), in
   Kazia Therapeutics : Corporate Governance Statement | MarketScreener  2020/08/27 04:52:04 MarketScreener
Kazia Therapeutics Limited Corporate Governance Statement for the year ended 30 June 2020 As at 27 August 2020 The… | August 27, 2020
   Kazia Therapeutics' paxalisib an Orphan Drug in U.S. for malignant glioma (NASDAQ:KZIA)  2020/08/24 04:36:13 Seeking Alpha
The FDA has granted Orphan Drug Designation (ODD) to Kazia Therapeutics' (NASDAQ:KZIA) paxalisib (formerly GDC-0084) for the treatment of malignant glioma,
   Kazia Therapeutics : paxalisib awarded Orphan Drug Designation | MarketScreener  2020/08/23 22:20:06 MarketScreener
ASX RELEASE 24 August 2020 US FDA AWARDS ORPHAN DRUG DESIGNATION TO PAXALISIB FOR MALIGNANT GLIOMA, INCLUDING DIPG … | August 23, 2020
   Biotech Kazia taps Bells for entitlement offer  2020/09/30 00:51:43 The Australian Financial Review
Sydney-based biotech outfit Kazia Therapeutics is hunting a $25.2 million cash injection, to fund its participation in an international bran cancer study.
   Kazia inks clinical pact with Dana-farber Cancer Institute for its lead asset in primary CNS lymphoma (NASDAQ:KZIA)  2020/09/22 15:35:17 Seeking Alpha
Kazia Therapeutics (KZIA +0.9%) has collaborated with Dana-Farber Cancer Institute (DFCI), to investigate its lead drug, paxalisib (formerly GDC-0084), in
   Kazia Therapeutics : Corporate Governance Statement | MarketScreener  2020/08/27 04:52:04 MarketScreener
Kazia Therapeutics Limited Corporate Governance Statement for the year ended 30 June 2020 As at 27 August 2020 The… | August 27, 2020
   Kazia Therapeutics' paxalisib an Orphan Drug in U.S. for malignant glioma (NASDAQ:KZIA)  2020/08/24 04:36:13 Seeking Alpha
The FDA has granted Orphan Drug Designation (ODD) to Kazia Therapeutics' (NASDAQ:KZIA) paxalisib (formerly GDC-0084) for the treatment of malignant glioma,
   Kazia Therapeutics : paxalisib awarded Orphan Drug Designation | MarketScreener  2020/08/23 22:20:06 MarketScreener
ASX RELEASE 24 August 2020 US FDA AWARDS ORPHAN DRUG DESIGNATION TO PAXALISIB FOR MALIGNANT GLIOMA, INCLUDING DIPG … | August 23, 2020
   Kazia Therapeutics : Corporate Governance Statement | MarketScreener  2020/08/27 04:52:04 MarketScreener
Kazia Therapeutics Limited Corporate Governance Statement for the year ended 30 June 2020 As at 27 August 2020 The… | August 27, 2020
   Kazia Therapeutics' paxalisib an Orphan Drug in U.S. for malignant glioma (NASDAQ:KZIA)  2020/08/24 04:36:13 Seeking Alpha
The FDA has granted Orphan Drug Designation (ODD) to Kazia Therapeutics' (NASDAQ:KZIA) paxalisib (formerly GDC-0084) for the treatment of malignant glioma,
   Kazia Therapeutics : paxalisib awarded Orphan Drug Designation | MarketScreener  2020/08/23 22:20:06 MarketScreener
ASX RELEASE 24 August 2020 US FDA AWARDS ORPHAN DRUG DESIGNATION TO PAXALISIB FOR MALIGNANT GLIOMA, INCLUDING DIPG … | August 23, 2020
   Kazia Therapeutics : Change in substantial holding | MarketScreener  2020/08/13 22:38:07 MarketScreener
604 page 1/2 15July2001 Form604 Corporations Act 2001 Section 671B Notice of change of interests… | August 14, 2020
   Kazia Therapeutics News: Why KZIA Stock Is Rocketing 43% Higher Today  2020/08/07 19:06:03 InvestorPlace
Kazia Therapeutics (KZIA) news for Friday includes a designation from the U.S. Food and Drug Administration sending KZIA stock flying high.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノボゲン KZIA Kazia Therapeutics Limited)

 twitter  (公式ツイッターやCEOツイッターなど)